| For: | Huynh T, Bui DM, Zhou TX, Hu KQ. Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years. World J Hepatol 2024; 16(7): 1009-1017 [PMID: 39086529 DOI: 10.4254/wjh.v16.i7.1009] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i7/1009.htm |
| Number | Citing Articles |
| 1 |
Balazs Fülöp, Janett Fischer, Magdalena Hahn, Albrecht Böhlig, Madlen Matz-Soja, Thomas Berg, Florian van Bömmel. Prospective Analysis of Safety and Efficacy of Tenofovir Alafenamide Fumarate (TAF) in European Real-World Patients with Chronic Hepatitis B: A Single-Centre Real-Word Cohort Study. Pathogens 2024; 13(9) doi: 10.3390/pathogens13090820
|
| 2 |
Han-Wen Zhang, Jun-Ling Wu, Yi Chen, Zhi-Zhuang Zhao, Shu-Huang Peng, Jing-Xuan Zhao, Xian-Ya Huang, Zhe Luan, Shu-Fang Wang, Jiang-Tao Liu, Gang Sun. From fibrosis regression to recompensation: bibliometric and clinical evidence mapping of disease modification in cirrhosis. Frontiers in Medicine 2026; 13 doi: 10.3389/fmed.2026.1921542
|
| 3 |
Hamid Ghorbani, Saina Adib Amin, Reza Jafarzadeh Esfehani, Mohammad Reza Hadizadeh, Raheleh Miri, Sanaz Ahmadi Ghezeldasht. Tenofovir and fibrosis improvement in chronic hepatitis B: insights from a case series. The Egyptian Journal of Internal Medicine 2026; 38(1) doi: 10.1186/s43162-026-00601-6
|